At the news
? BULLISHIMPACT 8/10 6-K filed Apr 13, 2026 at 07:55 ET
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival. The data support advancement toward a 2026 BLA filing, with a confirmatory Phase 3 trial ongoing.
- Trastuzumab pamirtecan met primary efficacy endpoint in Phase 2 cohort of 145 patients with HER2-expressing, recurrent endometrial cancer
- Confirmed objective response rate was 47.9% in centrally tested patients (n=96) with median progression-free survival of 8.1 months
- Drug showed activity across all HER2 expression levels including IHC1+ and IHC2+, addressing high unmet need where standard chemo has only 15% response rate
- Safety profile was manageable with 46.9% grade 3 treatment-related adverse events and 4.8% grade 3 interstitial lung disease
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access